More Press Releases
More Featured Articles and Inverviews
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Latest News
Latest News
Outlook Reports world
Featured Nanotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
CURRENCIES
